Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6284816 | 0.98 | SORD (0.31) | SORDKDM4ELMNAL3MBTL1 | |
| SCHEMBL12929415 | 0.66 | KDM4E (0.35) | SORDKDM4ELMNAL3MBTL1MAOB | |
| SCHEMBL6497291 | 0.66 | KDM4E (0.35) | SORDKDM4ELMNAL3MBTL1MAOB | |
| SCHEMBL5000576 | 0.65 | HSP90AA1 (0.40) | SORDKDM4ELMNAL3MBTL1MAOB | |
| SCHEMBL29118397 | 0.63 | MAOB (0.37) | SORDKDM4ELMNAL3MBTL1MAOB | |
| SCHEMBL2646639 | 0.63 | SORD (0.40) | SORDKDM4ELMNAL3MBTL1MAOB | |
| SCHEMBL1477438 | 0.61 | PLD1 (0.36) | SORDKDM4ELMNAL3MBTL1MAOB | |
| SCHEMBL2074811 | 0.60 | SORD (0.51) | SORDKDM4ELMNAL3MBTL1 | |
| SCHEMBL31014265 | 0.60 | SORD (0.51) | SORDKDM4ELMNAL3MBTL1 | |
| SCHEMBL2320496 | 0.60 | SORD (0.51) | SORDKDM4ELMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999063599-A1 | DYE SENSITIZED NANO-STRUCTURED PHOTO-VOLTAIC TANDEM CELL | LINDQUIST STEN ERIC (SE) | 1999-12-09 | — | — | WO | claimed |
| EP-4363423-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| CN-116262753-A | Novel PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2023-06-16 | — | — | CN | disclosed |
| WO-2023278326-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-4076667-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022063101-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-03-31 | — | — | WO | disclosed |
| EP-2872504-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| WO-1999063599-A1 | DYE SENSITIZED NANO-STRUCTURED PHOTO-VOLTAIC TANDEM CELL | LINDQUIST STEN ERIC (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SORD 650/4885KDM4E 2701/4885LMNA 4719/4885 |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | SORD 2166/4885KDM4E 4327/4885LMNA 3165/4885 |
| US-20230322791-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | SORD 3537/4885KDM4E 2160/4885LMNA 2403/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | SORD 2166/4885KDM4E 4327/4885LMNA 3165/4885 |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | SORD 3349/4885KDM4E 3721/4885LMNA 1979/4885 |
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | SORD 233/4885KDM4E 3445/4885LMNA 2743/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | SORD 650/4885KDM4E 2701/4885LMNA 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.